Blog
RSS FeedPosted by Michael Wonder on 17 Feb 2023
UK’s most expensive drug Libmeldy saved Teddi Shaw, but is too late for her sister
16 February 2023 - A toddler with a rare inherited condition has become the first child to be treated by ...
Posted by Michael Wonder on 17 Feb 2023
High drug prices are not justified by industry’s spending on research and development
15 February 2023 - Aris Angelis and colleagues argue that by refocusing their spending drug companies could provide more innovative ...
Posted by Michael Wonder on 17 Feb 2023
Teclistamab for the treatment of patients with relapsed or refractory multiple myeloma after three or more therapies
16 February 2023 - Another new cancer medicine becomes an assessment non-starter. ...
Posted by Michael Wonder on 17 Feb 2023
Mitapivat sulphate for the treatment of patients with pyruvate kinase deficiency
16 February 2023 - NICE is unable to make a recommendation on the the use of mitapivat sulphate (Pyrukynd) for the ...
Posted by Michael Wonder on 16 Feb 2023
NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines
16 February 2023 - NICE has today issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 ...
Posted by Michael Wonder on 16 Feb 2023
Living health technology assessments: how close to living reality?
16 February 2023 - HTA processes have remained largely unchanged, but innovative study designs (eg, pragmatic and adaptive clinical trials, single-arm ...
Posted by Michael Wonder on 16 Feb 2023
Tixagevimab and cilgavimab for the the prevention of COVID-19 disease
16 February 2023 - The Department of Health and Social Care has NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Feb 2023
Vutrisiran for the treatment of patients with hereditary transthyretin-related amyloidosis
15 February 2023 - NICE has published final draft guidance on the use of vutrisiran for the treatment of adults ...
Posted by Michael Wonder on 09 Feb 2023
Digital mental health tech for children and young people recommended by NICE in first rapid healthtech guidance
8 February 2023 - Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety ...
Posted by Michael Wonder on 09 Feb 2023
Lorlatinib for the first-line treatment of patients with ALK positive advanced non-small-cell lung cancer
9 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Feb 2023
Dapagliflozin propanediol monohydrate for the treatment of patients with chronic heart failure with preserved or mildly reduced ejection fraction
8 February 2023 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 09 Feb 2023
Empagliflozin for the treatment of patients with chronic heart failure with preserved or mildly reduced ejection fraction
8 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Feb 2023
NICE recommends genetic test to prevent newborn babies going deaf
9 February 2023 - A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a ...
Posted by Michael Wonder on 09 Feb 2023
Availability of Sanofi’s Nexviadyme (avalglucosidase alfa) provides NHS with new treatment for Pompe disease
8 February 2023 - Sanofi announced today that health care specialists and patients living with Pompe disease will now have ...
Posted by Michael Wonder on 08 Feb 2023
Regorafenib monohydrate for patients with previously treated metastatic colorectal cancer
8 February 2023 - Regorafenib monohydrate is recommended as an option for the treatment of adults with metastatic colorectal cancer who ...